Branded

American Regent, Provepharm Life Solutions intro ProvayBlue injection

ProvayBlue is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
AbbVie receives FDA nod for new indication of Skyrizi

Skyrizi is the first new treatment option in six years for moderately to severely active Crohn's disease.
Eli Lilly’s Olumiant receives FDA nod for new indication

This is the first FDA approval of a systemic treatment, which treats the entire body rather than a specific location, for alopecia areata.
Upsher-Smith wins HDA's DIANA award

Upsher-Smith was named Best Overall Branded Pharmaceutical Product Manufacturer with less than $300 million in sales.
Endo partners with TLC to commercialize treatment for osteoarthritis knee pain

Endo currently expects to launch the differentiated branded product in the United States in 2025.
Galderma releases Epsolay

The topical cream is for the treatment of bumps and blemishes (inflammatory lesions) of rosacea in adults.
FDA approves Roche’s Evrysdi for use in babies under 2 months old with SMA

Evrysdi is designed to treat SMA by increasing and sustaining the production of the survival motor neuron protein in the central nervous system and peripheral tissues.
FDA grants Servier approval for new indication of Tibsovo

Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

GSK obtains FDA approval for new indication for Benlysta